Healthcare Services

One of the Major Drivers of the Chronic Hepatitis B Market Is the High Prevalence Of Hepatitis B Infection

March 31, 2026April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Chronic Hepatitis B Market By 2030 Starting From Its 2026 Size?

The market size for chronic hepatitis B has demonstrated consistent growth in recent years. It is anticipated to expand from $3.93 billion in 2025 to $4.1 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.2%. Historically, this expansion has been driven by several factors, including enhanced hepatitis B screening programs, wider availability of antiviral drugs, increasing awareness concerning liver disease complications, greater utilization of nucleos(t)ide analogs, and the establishment of long-term disease monitoring protocols.

The chronic hepatitis b market size is expected to experience consistent growth in the coming years, projected to reach $4.74 billion by 2030, at a compound annual growth rate (CAGR) of 3.7%. This expansion during the forecast period can be attributed to increasing investments in next-generation HBV therapies, a rising demand for finite-duration treatment regimens, the development of therapeutic vaccines, a growing focus on eliminating viral reservoirs, and increased global hepatitis elimination initiatives. Key trends anticipated in the forecast period include the increasing adoption of long-term antiviral therapies, a rise in the development of functional cure approaches, a growing focus on early disease detection and monitoring, the expansion of immune-modulating treatment strategies, and enhanced patient adherence programs.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17112&type=smp

What Primary Drivers Are Shaping The Development Of The Chronic Hepatitis B Market?

The chronic hepatitis B virus market is anticipated to expand due to the widespread occurrence of chronic hepatitis B infection. Hepatitis B, a liver infection stemming from the hepatitis B virus (HBV), can be prevented by vaccination. The increase in hepatitis B infection rates, especially in low- and middle-income nations, is primarily caused by insufficient vaccination coverage, leading to higher transmission rates as a significant portion of the population lacks protection. Consequently, rising hepatitis B infection rates can boost the demand for diagnostic tests and treatment options. For example, a June 2024 report from the Centers for Disease Control and Prevention (CDC), a US-based government agency, indicated that raising global hepatitis B vaccination coverage to 90% and treatment access to 80% could prevent 26 million new infections and 9 million deaths attributable to hepatitis B between 2022 and 2050. In 2022, 1.2 million new cases of hepatitis B virus (HBV) infection were recorded. Therefore, the high prevalence of hepatitis B infection will propel the chronic hepatitis B virus market.

Which Segment Categories Define The Chronic Hepatitis B Market?

The chronic hepatitis b market covered in this report is segmented –

1) By Drug Class: Antivirals, Immune Modulators

2) By Gender: Male, Female

3) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers

Subsegments:

1) By Antivirals: Nucleos(T) Ide Analogs (Tenofovir, Entecavir), Interferons (Pegylated Interferon)

2) By Immune Modulators: Immune Checkpoint Inhibitors, Therapeutic Vaccines (HBV Vaccines Under Development)

Which Upcoming Trends Are Expected To Influence The Chronic Hepatitis B Market?

Major companies within the chronic hepatitis B market are primarily concentrating on advancements in technology, particularly new antiviral therapies. These novel antiviral therapies are innovative medications designed to combat viral infections, especially those resistant to current treatments, by preventing replication and utilizing advanced delivery methods, with ongoing clinical trials assessing their safety and effectiveness, such as bepirovirsen for chronic hepatitis B. For instance, in February 2024, GSK plc, a UK-based multinational pharmaceutical and biotechnology company known for its research, development, manufacturing, and marketing of a broad spectrum of healthcare products, obtained the U.S. Food and Drug Administration (FDA) Fast Track designation for bepirovirsen. This is an investigational antisense oligonucleotide (ASO) developed to treat chronic hepatitis B (CHB). Bepirovirsen functions by targeting and degrading the hepatitis B virus (HBV) RNA, which could enable the immune system to regain control over the infection. The drug has demonstrated encouraging outcomes in its Phase IIb trials, specifically the B-Clear and B-Sure studies, where it proved effective in lowering hepatitis B surface antigen (HBsAg) levels and achieving durable viral suppression.

Who Are The Top Companies Competing In The Chronic Hepatitis B Market?

Major companies operating in the chronic hepatitis b market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co Inc, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Dynavax Technologies Corporation, Gilead Sciences Inc, Viatris Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Apotex Corp, Cipla Ltd, Hikma Pharmaceuticals, Lupin Pharmaceuticals Inc, Vir Biotechnology Inc, VBI Vaccines Inc, Shenzhen Hepalink Pharmaceutical Co. Ltd., Accord Healthcare Inc, Par Pharmaceutical Inc, Arrowhead Pharmaceuticals Inc, ViiV Healthcare, Arbutus Biopharma Corporation, Ascentage Pharma, ENYO Pharma, Zydus Pharmaceuticals Inc, Nucorion Pharmaceuticals

Read the full chronic hepatitis b market report here:

https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report

How Does The Chronic Hepatitis B Market Perform Across Major Global Regions?

North America was the largest region in the chronic hepatitis B market in 2025. The regions covered in the chronic hepatitis b market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Chronic Hepatitis B Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=17112&type=smp

Browse Through More Reports Similar to the Global Chronic Hepatitis B Market 2026, By The Business Research Company

Chronic Disease Management Global Market Report

https://www.thebusinessresearchcompany.com/report/chronic-disease-management-global-market-report

Chronic Pain Global Market Report

https://www.thebusinessresearchcompany.com/report/chronic-pain-global-market-report

Chronic Care Management Software Global Market Report

https://www.thebusinessresearchcompany.com/report/chronic-care-management-software-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795